Alabama
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
California
Duarte; City of Hope
A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma
Duarte; City of Hope
A Phase I Study of Alefacept (Amevive) in the Treatment of Cutaneous-T-Cell Lymphoma and Peripheral T-Cell NHL
Stanford; Stanford Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Colorado
Denver, Boulder, Aurora, Colorado Springs; Rocky Mountain Cancer Center
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Connecticut
New Haven; Yale University
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Florida
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Various Cities; Research Sites
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Georgia
Atlanta; The Emory Clinic
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Illinois
Arlington Heights, Niles, Winfield; Cancer Care & Hematology Specialists of Chicagoland
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Chicago; Feinberg School of Medicine
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Indiana
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Iowa
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Louisiana
New Orleans; Tulane University Health Science Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Maryland
Baltimore; St Agnes Hospital
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Bethesda; Centers for Cancer and Blood Disorders
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Massachusetts
Boston; Boston Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Michigan
Detroit; Henry Ford Hospital
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Detroit; Henry Ford Health System
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Minnesota
Minneapolis, St. Paul, Burnsville, Edina, Maplewood, Woodbury; Minnesota Oncology Hematology, P.A.
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Missouri
Various Cities; Research Sites
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Nebraska
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
New York
New York; Memorial Sloan Kettering Cancer Center
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
New York; Memorial Sloan Kettering Cancer Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
New York; Biomedical Research Alliance of New York
Mount Sinai School of Medicine is currently recruiting subjects who have T-cell leukemia or lymphoma, who have failed two or more prior treatment regimens to participate in a clinical study to test the safety and efficacy of an experimental drug.
NY; New York University Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Syracuse; SUNY Upstate Medical University
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
North Carolina
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Ohio
Cleveland; University Hospital of Cleveland
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Columbus; Ohio State University
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Oregon
Portland; Oregon Health & Science University
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Various Cities; Research Sites
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Pennsylvania
Philadelphia; University of Pennsylvania Health System
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Tennessee
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Texas
Dallas; Baylor University Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Houston; U.T. M.D. Anderson Cancer Center
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Houston; MD Anderson Cancer Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Various Cities; Research Sites
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Washington
Various Cities; Research Sites
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Washington, DC
Washington; Washington Cancer Institute at Washington Hospital Center
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
Washington; Georgetown University
A Single-Agent Phase II Trial of Romidepsin (Depsipeptide) in the Treatment of Progressive or Relapsed Peripheral T-cell Lymphoma (PTCL)
International
Lyoin, France; Hôpital de L’Hôtel Dieu
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Nice, France; Hôpital Archet II
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Paris Cedex 10, France; Hôpital Saint-Louis
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Pierre Bénite, France; Centre Hospitalier Lyon Sud
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Essen, Germany; University of Essen, Dept. of Dermatology
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Kiel, GERMANY; University of Kiel
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Minden, Germany; Akademisches Lehrkrankenhaus der medizinischen Hochschule Hannover
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Würzburg, Germany; University of Würzburg
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Bologna, ITALY; Instituto di Ematologia e Oncologia Medica L. & A. Seragnoli
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Florence, ITALY; University of Florence Medical School Department of Dermatology
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Rome, ITALY; IDI-IRCCS
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Turin, Italy; University of Turin
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Madrid, SPAIN; Hospital Universitario de la Princesa
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Madrid, SPAIN; Maternidad Planta Baja
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
